Literature DB >> 27895775

High expression of CD39 in gastric cancer reduces patient outcome following radical resection.

Xiao-Yan Cai1, Xue-Fei Wang2, Jun Li1, Jiang-Nan Dong1, Jiang-Qi Liu1, Neng-Ping Li1, Bei Yun1, Rong-Long Xia1, Jing Qin2, Yi-Hong Sun2.   

Abstract

Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), also known as cluster of differentiation (CD)39, is the rate-limiting enzyme in the generation of immunosuppressive adenosine and is important in tumor progression. The present study evaluated the expression of CD39+ and CD39+ forkhead box P3 (FoxP3)+ regulatory T (Treg) cells in gastric cancer (GC), and determined their prognostic roles in patients with GC following radical resection. It was observed that CD39 was expressed at significantly higher rates in tumor tissues as compared with paired peritumoral tissues. Overexpression of tumor CD39 was correlated with overall survival (OS). Furthermore, CD39 expression in GC tissues exhibited a prognostic role in OS. The CD39+ FoxP3+/FoxP3+ ratio in tumor tissues was higher than that in paired peritumoral tissues, and CD39+ FoxP3+ Treg cells were a better prognostic indicator than FoxP3+ Treg cells for OS. Collectively, our study indicates that overexpression of CD39 in GC is a predictor of poor outcome for GC patients following radical resection. CD39+ FoxP3+ Treg cells are a potential target for cancer immunotherapy.

Entities:  

Keywords:  CD39; gastric cancer; prognosis

Year:  2016        PMID: 27895775      PMCID: PMC5104239          DOI: 10.3892/ol.2016.5189

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

2.  CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.

Authors:  Dianne Pulte; Richard R Furman; M Johan Broekman; Joan H F Drosopoulos; Harold S Ballard; Kim E Olson; Jorge R Kizer; Aaron J Marcus
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

3.  Characterization of NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes.

Authors:  Daniela B R Leal; Cristiane A Streher; Tiago N Neu; Fábio P Bittencourt; Cláudio A M Leal; José E P da Silva; Vera M Morsch; Maria R C Schetinger
Journal:  Biochim Biophys Acta       Date:  2004-10-06

4.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

6.  Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors:  Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism.

Authors:  Sabine Ring; Stephen J Oliver; Bruce N Cronstein; Alexander H Enk; Karsten Mahnke
Journal:  J Allergy Clin Immunol       Date:  2009-05-08       Impact factor: 10.793

8.  Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.

Authors:  Giuseppe Perrone; Pier Adelchi Ruffini; Vincenzo Catalano; Cathie Spino; Daniele Santini; Pietro Muretto; Chiara Spoto; Costantino Zingaretti; Valerio Sisti; Paolo Alessandroni; Paolo Giordani; Andrea Cicetti; Silvia D'Emidio; Sergio Morini; Annamaria Ruzzo; Mauro Magnani; Giuseppe Tonini; Carla Rabitti; Francesco Graziano
Journal:  Eur J Cancer       Date:  2008-07-09       Impact factor: 9.162

9.  Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations.

Authors:  Q Zhou; J Yan; P Putheti; Y Wu; X Sun; V Toxavidis; J Tigges; N Kassam; K Enjyoji; S C Robson; T B Strom; W Gao
Journal:  Am J Transplant       Date:  2009-07-28       Impact factor: 8.086

10.  Overexpression of CD39 and high tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in resectable gastric cancer.

Authors:  Xiao-Yan Cai; Xue-Fei Wang; Jun Li; Jiang-Nan Dong; Jiang-Qi Liu; Neng-Ping Li; Bei Yun; Rong-Long Xia
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more
  16 in total

1.  Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Authors:  Ryuma Tokunaga; Shu Cao; Madiha Naseem; Jae Ho Lo; Francesca Battaglin; Alberto Puccini; Martin D Berger; Shivani Soni; Joshua Millstein; Wu Zhang; Sebastian Stintzing; Fotios Loupakis; Chiara Cremolini; Volker Heinemann; Alfredo Falcone; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2018-09-13       Impact factor: 4.481

2.  Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.

Authors:  Julia Biz Willig; Débora Renz Barreto Vianna; Aline Beckenkamp; Liziane Raquel Beckenkamp; Jean Sévigny; Márcia Rosângela Wink; Andréia Buffon; Diogo André Pilger
Journal:  Purinergic Signal       Date:  2020-01-18       Impact factor: 3.765

Review 3.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

Review 4.  Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.

Authors:  Paola de Andrade Mello; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

Review 5.  What Else Can CD39 Tell Us?

Authors:  Hai Zhao; Cong Bo; Yan Kang; Hong Li
Journal:  Front Immunol       Date:  2017-06-22       Impact factor: 7.561

6.  The TGF-b/SOX4 axis and ROS-driven autophagy co-mediate CD39 expression in regulatory T-cells.

Authors:  Marlene C Gerner; Liesa S Ziegler; Ralf L J Schmidt; Martin Krenn; Fritz Zimprich; Keziban Uyanik-Ünal; Vassiliki Konstantopoulou; Sophia Derdak; Giorgia Del Favero; Ilse Schwarzinger; Kaan Boztug; Klaus G Schmetterer
Journal:  FASEB J       Date:  2020-04-22       Impact factor: 5.191

Review 7.  Targeting adenosine for cancer immunotherapy.

Authors:  Robert D Leone; Leisha A Emens
Journal:  J Immunother Cancer       Date:  2018-06-18       Impact factor: 13.751

Review 8.  Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.

Authors:  Shin Foong Ngiow; Arabella Young
Journal:  Front Immunol       Date:  2020-07-28       Impact factor: 7.561

Review 9.  Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective.

Authors:  Huang-Yu Yang; Chao-Yi Wu; Jonathan D Powell; Kun-Lin Lu
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

10.  Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML.

Authors:  F Brauneck; F Haag; R Woost; N Wildner; E Tolosa; A Rissiek; G Vohwinkel; J Wellbrock; C Bokemeyer; J Schulze Zur Wiesch; C Ackermann; W Fiedler
Journal:  Oncoimmunology       Date:  2021-06-21       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.